Journal of Clinical Oncology, Vol 15, 1938-1944, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Weekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide given for 5 months after cytoreductive surgery for advanced ovarian cancer

G Bolis, G Favalli, S Danese, F Zanaboni, G Mangili, C Scarabelli, S Tateo, MG Valsecchi, G Scarfone, G Richiardi, L Frigerio, M Melpignano, A Villa and F Parazzini
I Clinica Ostetrico Ginecologica, Universita di Milano, Italy.

PURPOSE: To compare the efficacy of a treatment with cisplatin plus cyclophosphamide given for 5 months and a short treatment with cisplatin alone in advanced ovarian cancer, we conducted a multicenter randomized clinical trial. PATIENTS AND METHODS: Eligibility criteria were as follows: first diagnosis of histologically confirmed invasive epithelial ovarian cancer of International Federation of Gynecology and Obstetric (FIGO) stage III-IV, age younger than 75 years, and Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2. Within 28 days of cytoreductive surgery, eligible women were randomly assigned treatment with weekly cisplatin 50 mg/m2 for nine courses or cisplatin 75 mg/m2 plus cyclophosphamide 750 mg/m2 every 21 days for six courses. RESULTS: A total of 607 women were entered onto the study. There was no difference in the response to treatment. Pathologic complete response (CR) was documented in 63 of the weekly cisplatin cases and 70 of the cisplatin plus cyclophosphamide group (chi 1(2) = 1.43; P = .23). The median follow-up time was 3 years. There were 151 and 148 deaths in the weekly cisplatin and cyclophosphamide plus cisplatin arms, respectively. Survival curves were similar in the two groups, with a 3- year percent survival estimate of 44.1 (SE = 3.4) in the weekly cisplatin and 44.6 (SE = 3.4) in the cisplatin plus cyclophosphamide group (log-rank test chi 1(2) = 0.004; P = .96). CONCLUSION: This study found that 2-month monochemotherapy treatment with cisplatin was as effective as 5-month polychemotherapy including cisplatin at a similar doses but different dose-intensity plus cyclophosphamide.

This article has been cited by other articles:

				W. P. McGuire III Current Status of Taxane and Platinum-Based Chemotherapy in Ovarian Cancer J. Clin. Oncol., May 15, 2003; 21(90100): 133s - 135. [Abstract] [Full Text] [PDF]

				R. E. Bristow, R. S. Tomacruz, D. K. Armstrong, E. L. Trimble, and F. J. Montz Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis J. Clin. Oncol., March 1, 2002; 20(5): 1248 - 1259. [Abstract] [Full Text] [PDF]

				K. Yamamoto, Y. Kikuchi, K. Kudoh, J. Hirata, T. Kita, and I. Nagata Treatment with Paclitaxel Alone Rather than Combination with Paclitaxel and Cisplatin May be Selective for Cisplatin-resistant Ovarian Carcinoma Jpn. J. Clin. Oncol., October 1, 2000; 30(10): 446 - 449. [Abstract] [Full Text] [PDF]

				F. M. Muggia, P. S. Braly, M. F. Brady, G. Sutton, T. H. Niemann, S. L. Lentz, R. D. Alvarez, P. R. Kucera, and J. M. Small Phase III Randomized Study of Cisplatin Versus Paclitaxel Versus Cisplatin and Paclitaxel in Patients With Suboptimal Stage III or IV Ovarian Cancer: A Gynecologic Oncology Group Study J. Clin. Oncol., January 5, 2000; 18(1): 106 - 106. [Abstract] [Full Text] [PDF]